References Chapter 12

  1. Abdool Karim SS et al. Integration of antiretroviral therapy with tuberculosis treatment. (SAPIT Study). N Engl J Med 2011 Oct 20; 365:1492.

  2. Havlir DV et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. (STRIDE Trial - ACTG A5221). N Engl J Med 2011 Oct 20; 365:1482.

  3. Blanc F-X et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. (CAMELIA Trial). N Engl J Med 2011 Oct 20; 365:1471.

  4. Suhashni Naiker, C Conolly, L Weisner, D Phillips, A Harries, C Lienhardt, H McIlleron, and A Pym. Pharmacokinetic Evaluation of Different Rifabutin Dosing Strategies in African TB Patients on Lopinavir/ritonavir-based ART. CROI 2011 Paper # 650.

  5. Zhang J, Zhu L. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir” J Antimicrob Chemother. 2011 Jun 28.

  6. Sundari Mase, Terence Chorba, Philip Lobue, Kenneth Castro. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis. MMWR Recommendations and Reports, October 25, 2013/62(rr09);1-12.

  7. Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013 Jun;57(6).

  8. World Health Organization. Technical update on treatment optimization. Use of efavirenz during pregnancy:a public health perspective. June 2012.